Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus NEBIVOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus NEBIVOLOL HYDROCHLORIDE.
BETAPACE vs NEBIVOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist with nitric oxide-mediated vasodilatory activity via stimulation of beta-3 receptors.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
5 mg orally once daily. May be initiated at 2.5 mg in patients with renal impairment or those at risk of hypotension. Titrate at 2-week intervals up to 40 mg once daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 12-19 hours in extensive metabolizers; up to 30-50 hours in poor CYP2D6 metabolizers; clinically, once-daily dosing is effective due to pharmacodynamic half-life >40 hours.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Approximately 38% renal, 48% fecal (unchanged drug and metabolites); extensive hepatic metabolism (CYP2D6) with glucuronidation; <1% excreted unchanged in urine.
Category C
Category A/B
Beta-Blocker
Beta-Blocker